Treatment of patients with chronic hepatitis C and normal alanine aminotransferase levels with peginterferon alfa-2a (40 KD) (Pegasys®) and ribavirin.

被引：0
|
作者：
Zeuzem, S
Diago-Madrid, M
Shiffman, ML
Reindollar, RW
Pockros, PJ
Gane, E
Tran, A
Farci, P
Lamour, F
机构：
[1] Univ Saarlandes Kliniken, Med Klin & Poliklin, Homburg, Germany
[2] Hosp Gen Valencia, Valencia, Spain
[3] Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA
[4] Carolinas Ctr Liver Dis, Charlotte, NC USA
[5] Scripps Clin, La Jolla, CA USA
[6] Middlemore Hosp, Grafton, New Zealand
[7] Hop Archet, Federat Hepatogastroenterol, Nice, France
[8] Univ Cagliari, Dipartiemt Med Sci, Cagliari, Italy
[9] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1680
引用
收藏
页码：583A / 583A
页数：1
相关论文
共 50 条
  • [1] Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    Zeuzem, S
    Diago, M
    Gane, E
    Reddy, KR
    Pockros, P
    Prati, D
    Shiffman, M
    Farci, P
    Gitlin, N
    O'Brien, CB
    Lamour, F
    Lardelli, P
    GASTROENTEROLOGY, 2004, 127 (06) : 1724 - 1732
  • [2] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [3] Cost-effectiveness of treating adults with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (PNALT) with peginterferon alfa-2a (40 kD) (Pegasys) plus ribavirin (Copegus)
    Hornberger, J
    Farci, P
    Prati, D
    Zuezem, S
    Patel, KK
    Green, J
    VALUE IN HEALTH, 2004, 7 (03) : 347 - 348
  • [4] Effect of ethnicity on the pharmacokinetics of ribavirin (COPEGUS®) and peginterferon alfa-2a (40kd) (PEGASYS®) in patients with chronic hepatitis C
    Brennan, B
    Morrison, R
    Hagedorn, C
    Marbury, TC
    Sulkowski, M
    Grippo, J
    Gries, JM
    HEPATOLOGY, 2005, 42 (04) : 652A - 653A
  • [5] International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40KD) (pegasys®) and ribavirin (copegus®).
    Zuezem, S
    Diago, M
    Gane, E
    Reddy, R
    Pockros, P
    Farci, P
    Gitlin, N
    Lamour, F
    Lardelli, P
    Shiffman, M
    HEPATOLOGY, 2003, 38 (04) : 208A - 208A
  • [6] Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels
    Pockros, PJ
    Diago, M
    Gane, E
    Reddy, KR
    Prati, D
    Shiffman, ML
    Farci, P
    O'Brien, C
    Lardelli, P
    Lamour, F
    Zeuzem, S
    JOURNAL OF HEPATOLOGY, 2004, 40 : 148 - 148
  • [7] Peginterferon alfa-2a (40 KD) (pegasys) plus ribavirin (copegus) is an efficacious and safe treatment for chronic hepatitis C (CHC) in patients with compensated cirrhosis
    Marcellin, P
    Brillanti, S
    Cheinquer, H
    Cooksley, WGE
    Shiffman, L
    Schmidt, WE
    Brunda, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 154 - 154
  • [8] Peginterferion alfa-2a (40KD) (Pegasys®) for the treatment of patients with chronic hepatitis C
    Ferenci, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (07) : 610 - 615
  • [9] Combination of Levovirin (LVV) and peginterferon alfa-2a (40 KD) (Pegasys®) fails to generate a virological response comparable to ribavirin (RBV, Copegus®) and peginterferon alfa-2a (40KD) in patients with chronic hepatitis
    Pockros, PJ
    Pessoa, MG
    Diago, M
    Martinelli, ADC
    Berg, T
    Germanidis, G
    Lai, MY
    Gomez, HR
    Goeser, T
    Roberts, S
    Sheen, IS
    Hsien, T
    Hinrichsen, HM
    Lee, SS
    Reindollar, R
    Sola, R
    Wilson, K
    Jorga, K
    Graham, P
    Jackson, H
    HEPATOLOGY, 2004, 40 (04) : 391A - 391A
  • [10] Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in patients with or without drug use
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Bernd
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A840
12345